id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
zmU1yq1MEem3ETODDt0tAQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,diabetes mellitus,oncomitant clinical conditions (,", inflammation, hypercoagulable ",TextQuoteSelector,TextPositionSelector,19980,19997,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:21:39.901006+00:00
zchTIK1OEemncQ8_9Mz4yA,jgraPEon,https://europepmc.org/articles/PMC3231843/,platelet receptors ,volves its interaction with two ,belonging to the P2 purinergic f,TextQuoteSelector,TextPositionSelector,11376,11395,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:35:57.990872+00:00
zEJ59q1CEemiqI-OqG3aXQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,PLC," shape change, phospholipase C (",") activation, thromboxane A2 (T×",TextQuoteSelector,TextPositionSelector,14756,14759,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:10:00.996054+00:00
yqO_1rRHEemGxK_iJz62Kg,jgraPEon,https://europepmc.org/articles/PMC3231843/, P2Y12 platelet receptor,opidogrel irreversibly binds the, after a two-step activation by ,TextQuoteSelector,TextPositionSelector,17857,17881,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:33:24.214196+00:00
ybIjPq1NEem4lGcJ4NoBuQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,integrin αIIbβ3 ,CD40L) is released and binds to ,"on activated platelets, thus pro",TextQuoteSelector,TextPositionSelector,52942,52958,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:28:41.734058+00:00
yOxg8q1KEemTNpfV8HHX0g,jgraPEon,https://europepmc.org/articles/PMC3231843/,myocardial infarction,",000 subjects with a history of ",", will evaluate the efficacy of ",TextQuoteSelector,TextPositionSelector,43720,43741,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:07:11.772111+00:00
y7VIPK1IEem3B2e4DgVvuQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,Axl,"RTKs) of the TAM family (Tyro3, ",", MerTK); through its vitamin K-",TextQuoteSelector,TextPositionSelector,27162,27165,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:52:57.492467+00:00
xSIg0q1BEemXuM_oMy05vg,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gαi, activation of both the Gαq and , pathways by ADP is needed for p,TextQuoteSelector,TextPositionSelector,11547,11550,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:02:40.045380+00:00
xAhtFq1OEemkO3epu_QZ_w,jgraPEon,https://europepmc.org/articles/PMC3231843/,platelet receptor,el irreversibly binds the P2Y12 , after a two-step activation by ,TextQuoteSelector,TextPositionSelector,17864,17881,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:35:41.286048+00:00
x3BIjq1JEemqwwet-cudnA,jgraPEon,https://europepmc.org/articles/PMC3231843/,phospholipase C,"r, which leads to shape change, "," (PLC) activation, thromboxane A",TextQuoteSelector,TextPositionSelector,14739,14754,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:59:59.779998+00:00
wZGsKq1MEemX0HO4u4vIug,jgraPEon,https://europepmc.org/articles/PMC3231843/,CYP3A4 ,ve metabolite (AR-C124910XX) by ,enzymes. Being both ticagrelor a,TextQuoteSelector,TextPositionSelector,37213,37220,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:21:18.605394+00:00
w6AxFtCOEemf4xvt1AtN9A,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gaq-coupled P2Y1,tReceptor(s)Effect(s)CommentsADP,; Gai-coupled P2Y12P2Y1: shape c,TextQuoteSelector,TextPositionSelector,10558,10574,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:11:59.367463+00:00
vNG9pK1JEempIEf_zFw5dA,jgraPEon,https://europepmc.org/articles/PMC3231843/,hirudin,PAR-1 and PAR-4. By binding the ,-like extracellular amino termin,TextQuoteSelector,TextPositionSelector,13145,13152,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:59:41.441748+00:00
vG4ZfK1CEemTIDfHMbSntg,jgraPEon,https://europepmc.org/articles/PMC3231843/,thrombin receptor, terminal domain (the so-called ,"), thrombin activates platelets ",TextQuoteSelector,TextPositionSelector,13209,13226,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:09:34.926079+00:00
vAtA2K1KEemZ8gcZpe5Zyg,jgraPEon,https://europepmc.org/articles/PMC3231843/,hyperuricemia,d with caution in patients with ,", bradyar-rhythmias without pace",TextQuoteSelector,TextPositionSelector,42181,42194,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:06:49.681245+00:00
ubX9zK1LEemSM4cM3PHWig,jgraPEon,https://europepmc.org/articles/PMC3231843/,(CYP) 2C19,notyping of the cytochrome P450 ," (*1,*2,*3,*4,*5,*6,*7,*8,*17) w",TextQuoteSelector,TextPositionSelector,38125,38135,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:13:55.752765+00:00
u0uGvq1NEem3FA8nAEwJMQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,injury,latelet recruitment at sites of , (3). It may also play a pro-coa,TextQuoteSelector,TextPositionSelector,14255,14261,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:28:17.558195+00:00
thZKhq1MEemmbNv5e3MK2w,jgraPEon,https://europepmc.org/articles/PMC3231843/,cyclo-oxygenase ,show that platelets with intact ,activity can be detected into th,TextQuoteSelector,TextPositionSelector,21930,21946,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:20:59.236025+00:00
tLCCPNCOEemC168EItotxw,jgraPEon,https://europepmc.org/articles/PMC3231843/,T× synthase,by cyclooxygenase 1 (COX-1) and ,", further amplifies platelet act",TextQuoteSelector,TextPositionSelector,12484,12495,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:11:34.424427+00:00
soal_K1KEemUO0evOJphTw,jgraPEon,https://europepmc.org/articles/PMC3231843/,hypotension,"ng ticagrelor. Dyspnea, nausea, ",", and asymptomatic ventricular p",TextQuoteSelector,TextPositionSelector,41956,41967,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:06:34.062070+00:00
slO7fK1CEemnxjPKZICQAQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,PAR-4,asodilating agentThrombinPAR-1; , (secondary); GpIbαShape change;,TextQuoteSelector,TextPositionSelector,10886,10891,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:09:17.928268+00:00
s3oo_q1OEempEsvCcvVLTA,jgraPEon,https://europepmc.org/articles/PMC3231843/,phosphoinositide-3 kinase,"77). Active MMP-2, potentiating "," activation, amplifies platelet ",TextQuoteSelector,TextPositionSelector,52362,52387,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:35:13.847325+00:00
rJZbVK1MEem3EIMOeSGWCw,jgraPEon,https://europepmc.org/articles/PMC3231843/,Cyclooxygenase,sustained platelet aggregation. , (COX)-l catalyzes the productio,TextQuoteSelector,TextPositionSelector,14911,14925,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:20:43.387268+00:00
rBSMaq1LEemQBg9_TzecJw,jgraPEon,https://europepmc.org/articles/PMC3231843/,(COX)-l ,let aggregation. Cyclooxygenase ,catalyzes the production of T×A2,TextQuoteSelector,TextPositionSelector,14926,14934,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:13:32.872489+00:00
qvYtNq1OEemaCi-67KRmlQ,jgraPEon,https://europepmc.org/articles/PMC3231843/, phosphoinositide 3-kinase,"orylated VASP, and activation of", are blocked. The net result is ,TextQuoteSelector,TextPositionSelector,36649,36675,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:34:59.620462+00:00
qY0Nnq1NEempKOvtBFVWOg,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gβi,. By blocking Gαq via PAR-1 and ," via P2Y12, combined inhibition ",TextQuoteSelector,TextPositionSelector,13927,13930,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:27:47.669364+00:00
qGyZ8K1KEemZ_ldF42itSw,jgraPEon,https://europepmc.org/articles/PMC3231843/,intracranial bleedings," 3.8%; P=0.03), including fatal ",", were detected in subjects on t",TextQuoteSelector,TextPositionSelector,41313,41335,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:06:17.421195+00:00
q9wOCK1BEemP_vPFWSeDMg,jgraPEon,https://europepmc.org/articles/PMC3231843/, P-selectin , change; ADP and T×A2 secretion;,expression; αIIbβ3 integrin rece,TextQuoteSelector,TextPositionSelector,10947,10959,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:01:57.642782+00:00
pG_OdK1CEemVXhMVPvFT5g,jgraPEon,https://europepmc.org/articles/PMC3231843/,ischemic stroke,"s (acute myocardial infarction, ","). In view of this, platelets ar",TextQuoteSelector,TextPositionSelector,8308,8323,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:08:54.577941+00:00
oRn9YK1OEemwwzf963EJOQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,phosphodiesterase type 3 ,"lostazol, selectively targeting ","(PDE3) and, then, determining in",TextQuoteSelector,TextPositionSelector,24432,24457,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:34:43.085423+00:00
nzrB4K1KEem6Si-_jqZmNA,jgraPEon,https://europepmc.org/articles/PMC3231843/, liver dysfunction,nducers as well as a significant, may be of concern for its use (,TextQuoteSelector,TextPositionSelector,37443,37461,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:06:01.116146+00:00
nl2Z6q1LEemwYnfmqajCQw,jgraPEon,https://europepmc.org/articles/PMC3231843/,bleeding tendency,ed with a worse safety (greater ,).A concerted effort that takes ,TextQuoteSelector,TextPositionSelector,55222,55239,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:13:10.019046+00:00
nTwihq1JEema3tMUcJygdA,jgraPEon,https://europepmc.org/articles/PMC3231843/, atheroma,e properties. At the site of the," rupture, platelet-released T×A2",TextQuoteSelector,TextPositionSelector,12762,12771,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:58:48.920212+00:00
nQ_2HK1NEem6UMuLkC5fNg,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gαq-coupled receptor,"o the P2 purinergic family, the ", P2Y1 and the Gαi-coupled recept,TextQuoteSelector,TextPositionSelector,11438,11458,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:27:26.780939+00:00
m_i3Kq1BEemwrPvUHfYT2g,jgraPEon,https://europepmc.org/articles/PMC3231843/,ischemia,"I, silent AMI, severe recurrent ",", stroke, and death. However, th",TextQuoteSelector,TextPositionSelector,39252,39260,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:01:31.053009+00:00
mRbv6LRGEemgR3s8BWp-sQ,jgraPEon,https://europepmc.org/articles/PMC3231843/, 5-HT platelet receptors,late is a selective inhibitor of,". In the S-ACCESS trial (64), 1,",TextQuoteSelector,TextPositionSelector,44477,44501,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:24:51.708318+00:00
lX6eoK1LEemQFVuiDvFTsw,jgraPEon,https://europepmc.org/articles/PMC3231843/,humans,ment of thrombotic disorders in ," (88). Individual bleeding risk,",TextQuoteSelector,TextPositionSelector,55027,55033,CRT_OG,no,CRT_OG,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:12:55.023645+00:00
lDYMqK1CEem25jPRTYnreA,jgraPEon,https://europepmc.org/articles/PMC3231843/,acute myocardial infarction,o acute ischemic complications (,", ischemic stroke). In view of t",TextQuoteSelector,TextPositionSelector,8279,8306,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:08:27.451075+00:00
kxi2Lq1KEemaWWcfnZd68w,jgraPEon,https://europepmc.org/articles/PMC3231843/,kidney failure,no dose adjustment is needed in ,". On the other hand, the concomi",TextQuoteSelector,TextPositionSelector,37334,37348,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:05:41.301110+00:00
kw_YUq1JEemyJG8u94Is7Q,jgraPEon,https://europepmc.org/articles/PMC3231843/,cyclooxygenase 1 ,erated from arachidonic acid by ,"(COX-1) and T× synthase, further",TextQuoteSelector,TextPositionSelector,12441,12458,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:58:31.663868+00:00
koiXMK1NEemQGPvffUEvVA,jgraPEon,https://europepmc.org/articles/PMC3231843/, Gαi-linked ADP receptor,"t by secreted ADP, acting on the",. By blocking Gαq via PAR-1 and ,TextQuoteSelector,TextPositionSelector,13871,13895,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:27:08.971774+00:00
kd6uSq1OEempEfs-272YLw,jgraPEon,https://europepmc.org/articles/PMC3231843/,PARs,d protease-activated receptors (,) for thrombin: PAR-1 and PAR-4.,TextQuoteSelector,TextPositionSelector,13093,13097,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:34:17.412836+00:00
kYHaWq1MEem4kGOuN9l-EA,jgraPEon,https://europepmc.org/articles/PMC3231843/,collagen ,orsOrally activeDZ-697bInhibits ,and ristocetin-mediated platelet,TextQuoteSelector,TextPositionSelector,26682,26691,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:19:57.964952+00:00
jwLc8LRHEem1IC9Owb1hOw,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gai-coupled receptors,Y12 cross-reaction (via Gαq and ,)Serotonin5HT-2A receptorsShape ,TextQuoteSelector,TextPositionSelector,11060,11081,"WT_DS,GP",no,[WT_DS][GP],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:31:44.339761+00:00
iUlyBq1JEem-avcYRRBlGw,jgraPEon,https://europepmc.org/articles/PMC3231843/,cardiovascular disease,r target for pharmacotherapy in ,.In spite of a significant antit,TextQuoteSelector,TextPositionSelector,12170,12192,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:58:15.290146+00:00
iRo-dq1LEemwvGeM4OVJOQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,thrombotic disorders ,newer strategy for treatment of ,in humans (88). Individual bleed,TextQuoteSelector,TextPositionSelector,55003,55024,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:12:34.338148+00:00
hflejK1NEemJrntqEo_MLg,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gαi-coupled receptors ,"latelet activation, and Gαq and ",are involved in this process. Th,TextQuoteSelector,TextPositionSelector,13729,13751,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:26:48.094240+00:00
hD8HjK1MEemqydO_DkJhbQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,CD 154,ibition.The CD40 ligand (CD40L; ,) is a trans-membrane protein ex,TextQuoteSelector,TextPositionSelector,52765,52771,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:19:35.259998+00:00
gzLVdNCPEemCMR-oLHLPkw,jgraPEon,https://europepmc.org/articles/PMC3231843/,GP IIb/IIIa receptor,"AMP) production, which mediates "," activation, leading to sustaine",TextQuoteSelector,TextPositionSelector,15683,15703,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:17:20.853586+00:00
gWbrGK1OEem4eHuL75090w,jgraPEon,https://europepmc.org/articles/PMC3231843/, PAR-1 receptor,cular targets. Thrombin binds to,", which leads to shape change, p",TextQuoteSelector,TextPositionSelector,14693,14708,WS_GP,yes,[WS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:33:49.857399+00:00
gQBW9LRIEemXOPPVtg0ahw,jgraPEon,https://europepmc.org/articles/PMC3231843/,TPb,"5-HT, T×A2, and thrombinT×A2TPa;", (secondary)Shape change; platel,TextQuoteSelector,TextPositionSelector,10688,10691,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:38:30.406227+00:00
g8_94q1CEemP74stqKKU2g,jgraPEon,https://europepmc.org/articles/PMC3231843/,CYP2C19,variety of polymorphisms in the , gene (most often the CYP2C19*2),TextQuoteSelector,TextPositionSelector,20728,20735,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:07:59.691095+00:00
fvd4mK1JEemUOI8ycj7Ksw,jgraPEon,https://europepmc.org/articles/PMC3231843/,thrombi, the formation of platelet-rich ," that, occluding the arterial lu",TextQuoteSelector,TextPositionSelector,10333,10340,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:57:58.248382+00:00
ft_trK1LEemSMl_ZJrxzHg,jgraPEon,https://europepmc.org/articles/PMC3231843/,acute coronary syndromes,nt has only been efficacious in ,". In addition, newer thienopyrid",TextQuoteSelector,TextPositionSelector,54332,54356,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:12:16.806689+00:00
fLvlmq1KEemsRm9QrSrowg,jgraPEon,https://europepmc.org/articles/PMC3231843/,intracranial hemorrhage,being associated with increased ,"), in elderly patients (aged ≥ 7",TextQuoteSelector,TextPositionSelector,34282,34305,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:05:04.061841+00:00
eQkmDq1MEem3D59JJFqAQw,jgraPEon,https://europepmc.org/articles/PMC3231843/,CAD,s with coronary artery disease (,) and PCI. Several methods were ,TextQuoteSelector,TextPositionSelector,19496,19499,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:19:16.718715+00:00
eFUCBK1NEemUkWsFhtRMPA,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gαi-coupled receptor ,q-coupled receptor P2Y1 and the ,P2Y12. The concomitant activatio,TextQuoteSelector,TextPositionSelector,11472,11493,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:26:25.051761+00:00
dku8yq1BEemci8fseKe3Uw,jgraPEon,https://europepmc.org/articles/PMC3231843/,Thrombotic,platelet drugsGo to:Introduction, (ischemic) complications of ath,TextQuoteSelector,TextPositionSelector,9529,9539,WT_DS,yes,[WT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:00:27.686466+00:00
dYZpTK1CEemwT1NQxZ0EWw,jgraPEon,https://europepmc.org/articles/PMC3231843/,cytochrome P450, after a two-step activation by , (CYP) liver isoenzymes. While t,TextQuoteSelector,TextPositionSelector,17913,17928,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:07:35.986094+00:00
cNrwwq1KEemaV48_eMnm5w,jgraPEon,https://europepmc.org/articles/PMC3231843/,unstable angina , found both among patients with ,and non-STEMI and STEMI subjects,TextQuoteSelector,TextPositionSelector,32216,32232,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:04:43.893511+00:00
b9ySQq1LEem_cFdHlXVX2Q,jgraPEon,https://europepmc.org/articles/PMC3231843/, CD40,1). Therapeutic targeting of the,-CD40L axis using humanized anti,TextQuoteSelector,TextPositionSelector,53054,53059,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:11:52.011792+00:00
b9FakLRIEem87196OjsN0Q,jgraPEon,https://europepmc.org/articles/PMC3231843/,t-PA,e tissue plasminogen activator (,") alone, or cangrelor (35, 140, ",TextQuoteSelector,TextPositionSelector,35615,35619,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:38:01.540071+00:00
au3XXK1OEemYw0f6ICgvUg,jgraPEon,https://europepmc.org/articles/PMC3231843/,PAD,ic peripheral arterial disease (,"), clopidogrel administered alon",TextQuoteSelector,TextPositionSelector,18142,18145,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:33:11.972472+00:00
amrMaq1MEemwv1MaBMMjSg,jgraPEon,https://europepmc.org/articles/PMC3231843/,atherosclerotic disease,trial (200 subjects with stable ,) (54) showed ticagrelor (100 mg,TextQuoteSelector,TextPositionSelector,38813,38836,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:18:52.313248+00:00
ai-Z4q1CEemouEsv5dERhA,jgraPEon,https://europepmc.org/articles/PMC3231843/,Human, major platelet activators (8). , platelets express two cell surf,TextQuoteSelector,TextPositionSelector,13004,13009,CRT_OG,yes,[CRT_OG][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:07:16.841461+00:00
aOZ7GK1NEemmbbctcErMjw,jgraPEon,https://europepmc.org/articles/PMC3231843/,growth arrest-specific gene 6,d aggregationOrally activeGas6 (,)Vitamin K-dependent protein; a ,TextQuoteSelector,TextPositionSelector,26767,26796,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:25:59.175463+00:00
_4bonq1AEemcirO4btweIg,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gas6,ion and aggregationOrally active, (growth arrest-specific gene 6),TextQuoteSelector,TextPositionSelector,26761,26765,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:57:08.585886+00:00
ZiSIfK1BEema0wfgZ-PnUA,jgraPEon,https://europepmc.org/articles/PMC3231843/,VASP,ator-stimulated phosphoprotein (,)-tailored clopidogrel loading d,TextQuoteSelector,TextPositionSelector,23294,23298,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:00:00.761081+00:00
ZV5-ZK1DEemLK4ePiUUFCA,jgraPEon,https://europepmc.org/articles/PMC3231843/,Tyro3,nases (RTKs) of the TAM family (,", Axl, MerTK); through its vitam",TextQuoteSelector,TextPositionSelector,27155,27160,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:14:18.429833+00:00
XikHeq1KEemUOsepEOXKXg,jgraPEon,https://europepmc.org/articles/PMC3231843/,PI3K ,oteinases (MMPs)By potentiating ,"activation, MMP-2 amplifies plat",TextQuoteSelector,TextPositionSelector,27323,27328,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:04:12.545403+00:00
XiQNMK1NEem41-sZxxh8Ww,jgraPEon,https://europepmc.org/articles/PMC3231843/, G-protein-coupled protease-activated receptors,atelets express two cell surface, (PARs) for thrombin: PAR-1 and ,TextQuoteSelector,TextPositionSelector,13044,13091,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:25:40.786999+00:00
XZJwsq1PEemn3-cmNx3jYA,jgraPEon,https://europepmc.org/articles/PMC3231843/, αIIbβ3 integrin receptor,ecretion; P-selectin expression;,; platelet activationPAR-1 and P,TextQuoteSelector,TextPositionSelector,10970,10995,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:39:58.943893+00:00
WulF3K1MEemUkKfUjwUn8w,jgraPEon,https://europepmc.org/articles/PMC3231843/,AMI,"), acute myocardial infarction (","), ischemic stroke) are the lead",TextQuoteSelector,TextPositionSelector,9645,9648,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:18:26.254079+00:00
WqijkK1OEemtLrtlzWLeZQ,jgraPEon,https://europepmc.org/articles/PMC3231843/, P2Y12 receptor,", whereas the signaling from the", facilitates sustained irreversi,TextQuoteSelector,TextPositionSelector,11737,11752,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:32:44.688763+00:00
WqULhK1BEemUf1fB3rrUMg,jgraPEon,https://europepmc.org/articles/PMC3231843/,coronary artery disease,"outcome in ≈4,500 patients with ", (CAD) and PCI. Several methods ,TextQuoteSelector,TextPositionSelector,19471,19494,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:59:41.346939+00:00
WTLjGq1CEemULd-w2wecpA,jgraPEon,https://europepmc.org/articles/PMC3231843/,5HT-2A, Gai-coupled receptors)Serotonin, receptorsShape change; platelet,TextQuoteSelector,TextPositionSelector,11091,11097,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:06:48.470155+00:00
VwRqhLRIEemmlIOYVM6CFw,jgraPEon,https://europepmc.org/articles/PMC3231843/,TPa," by 5-HT, T×A2, and thrombinT×A2",;TPb (secondary)Shape change; pl,TextQuoteSelector,TextPositionSelector,10684,10687,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:37:19.692455+00:00
VwCjpq1DEemqtXswm5b4_Q,jgraPEon,https://europepmc.org/articles/PMC3231843/,diabetic angiopathy,culation has been documented in , or in patients with coronary ar,TextQuoteSelector,TextPositionSelector,22127,22146,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:13:54.202061+00:00
UzdH9K1LEemmdzuISQZ6eA,jgraPEon,https://europepmc.org/articles/PMC3231843/,Transmembrane protein ,and blunting platelet reactivity,expressed on the surface of acti,TextQuoteSelector,TextPositionSelector,27792,27814,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:11:03.920641+00:00
Uz-saq1PEemcqdPA10kupQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,αIIbβ3 integrin,"on, glycoprotein (Gp) IIb/IIIa (",) mediates platelet aggregation ,TextQuoteSelector,TextPositionSelector,10109,10124,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:39:41.891617+00:00
UhC_wK1NEem3E_-ZK4cYxw,jgraPEon,https://europepmc.org/articles/PMC3231843/, GpIIb/ Ilia receptor,"rel, cangrelor, ticagrelor), and"," antagonists (abciximab, eptifib",TextQuoteSelector,TextPositionSelector,15949,15970,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:25:20.645427+00:00
UdrJhq1KEemQEd80sLxPDA,jgraPEon,https://europepmc.org/articles/PMC3231843/,thromboembolism,i-Gas6 antibody lowers platelet , induced by the intravenous inje,TextQuoteSelector,TextPositionSelector,26874,26889,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:03:51.667219+00:00
TNBhdK1CEemot09CBgPfQw,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gai-coupled P2Y12,(s)CommentsADPGaq-coupled P2Y1; ,P2Y1: shape change; P2Y12: aggre,TextQuoteSelector,TextPositionSelector,10562,10579,"WT_DS,GP",no,[WT_DS][GP],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:06:27.741753+00:00
TH4CTK1JEemLN_PcJKcUgw,jgraPEon,https://europepmc.org/articles/PMC3231843/,acute coronary syndrome,mplications of atherosclerosis (," (ACS), acute myocardial infarct",TextQuoteSelector,TextPositionSelector,9585,9608,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:56:33.608483+00:00
T7QT8K1BEem4u6sdZuHLBQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,COX-1,"ggregationIn endothelial cells, ",-derived PGH2 is converted into ,TextQuoteSelector,TextPositionSelector,10781,10786,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:59:23.011170+00:00
SYCIsq1OEemkOYsu4VGYJg,jgraPEon,https://europepmc.org/articles/PMC3231843/,P2Y12,oupled P2Y12P2Y1: shape change; ,: aggregationP2Y12 amplifies agg,TextQuoteSelector,TextPositionSelector,10599,10604,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:32:15.740962+00:00
SPphIq1LEem4bMvONi2Pdw,jgraPEon,https://europepmc.org/articles/PMC3231843/,trans-membrane protein,D40 ligand (CD40L; CD 154) is a , expressed on the surface of act,TextQuoteSelector,TextPositionSelector,52778,52800,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:10:46.632505+00:00
SD9ScLRIEemQrluoY0K8sQ,jgraPEon,https://europepmc.org/articles/PMC3231843/, TAM membrane receptors,oxy-terminal LG domains with the,. Studies indicate an associatio,TextQuoteSelector,TextPositionSelector,51696,51719,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:36:55.227735+00:00
RuCHoK1KEemoxhNabT3RFQ,jgraPEon,https://europepmc.org/articles/PMC3231843/, interleukin 6 ,inflammatory markers (sCD40L and,and the expression of P-selectin,TextQuoteSelector,TextPositionSelector,26518,26533,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:03:33.477484+00:00
Rn6rzq1BEemtF4dpspMBDw,jgraPEon,https://europepmc.org/articles/PMC3231843/,fibrinogen,ation and spreading by means of ," bridges, which, once converted ",TextQuoteSelector,TextPositionSelector,10182,10192,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:59:07.667146+00:00
RgCK_q1MEem_dcuXOAbOaw,jgraPEon,https://europepmc.org/articles/PMC3231843/,ADP-receptor,y of agonists in an aspirin- or , antagonist-independent fashion ,TextQuoteSelector,TextPositionSelector,52482,52494,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:17:51.262511+00:00
R_hn9K1NEemcqBvLcxX1Tg,jgraPEon,https://europepmc.org/articles/PMC3231843/,GpIbα,rombinPAR-1; PAR-4 (secondary); ,Shape change; ADP and T×A2 secre,TextQuoteSelector,TextPositionSelector,10905,10910,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:25:04.086190+00:00
REjMWq1PEem3AP9p0UAT9A,jgraPEon,https://europepmc.org/articles/PMC3231843/,vitamin K-dependent proteins,"e 6), a member of the family of ",", is stored in platelet α granul",TextQuoteSelector,TextPositionSelector,51160,51188,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:39:16.762840+00:00
Pcn7EK1KEemwuodbIxnU1g,jgraPEon,https://europepmc.org/articles/PMC3231843/,hemorrhagic stroke,"come), and with a lower risk of ", (0.53% versus 2.01%; RR 0.26; 9,TextQuoteSelector,TextPositionSelector,25011,25029,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:03:18.247583+00:00
PcSeuq1DEemsMW-HY8GQEw,jgraPEon,https://europepmc.org/articles/PMC3231843/,diabetes,it being found in patients with ,", with coronary stents, or with ",TextQuoteSelector,TextPositionSelector,34801,34809,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:13:12.014218+00:00
PW2Vxq1MEempCiM7dUEL_g,jgraPEon,https://europepmc.org/articles/PMC3231843/,ADP receptor,"d ADP, acting on the Gαi-linked ",. By blocking Gαq via PAR-1 and ,TextQuoteSelector,TextPositionSelector,13883,13895,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:17:36.488748+00:00
P8j1-tCMEemsDoMqBAG51A,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gaq-coupled P2Y1,tReceptor(s)Effect(s)CommentsADP,; Gai-coupled P2Y12P2Y1: shape c,TextQuoteSelector,TextPositionSelector,10558,10574,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T09:53:59.267757+00:00
P2NCrq1CEemTHcMXyI_cOw,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gai,hape change. P2Y12 is linked to ,-coupled signaling cascades asso,TextQuoteSelector,TextPositionSelector,15512,15515,"WT_DS,GP",no,[WT_DS][GP],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:06:05.123603+00:00
OuTP3K1LEemYgIv-wanLgA,jgraPEon,https://europepmc.org/articles/PMC3231843/,growth factor,oagulant activity (74). Being a ,"-like molecule, as it interacts ",TextQuoteSelector,TextPositionSelector,51375,51388,WT_GP,no,[WT_GP],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:10:22.659567+00:00
Os5JBq1BEemYpkvJQKt_DA,jgraPEon,https://europepmc.org/articles/PMC3231843/, myocardial infarction,mg/d). While the thrombolysis in, (TIMI) major bleeding was simil,TextQuoteSelector,TextPositionSelector,29402,29424,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:58:48.042667+00:00
OpT1HK1PEem2_8M7Q0VxmA,jgraPEon,https://europepmc.org/articles/PMC3231843/,Vitamin K-dependent protein, (growth arrest-specific gene 6),; a polyclonal anti-Gas6 antibod,TextQuoteSelector,TextPositionSelector,26797,26824,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:39:00.445203+00:00
NLXTkq1OEemQCr_UiQieMg,jgraPEon,https://europepmc.org/articles/PMC3231843/,P2Y1 receptor,on to occur. Signaling from the , causes platelet shape change an,TextQuoteSelector,TextPositionSelector,11631,11644,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:31:41.128740+00:00
N7xLCK1NEemZ-kf1cZDYQA,jgraPEon,https://europepmc.org/articles/PMC3231843/,GP IIb," C (PKC) activation, leading to ",/IIIa activation and transient p,TextQuoteSelector,TextPositionSelector,15398,15404,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:24:36.044848+00:00
Mpv6hq1KEemwYU_zyKFuwQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,PDE3,eting phosphodiesterase type 3 (,") and, then, determining intrace",TextQuoteSelector,TextPositionSelector,24458,24462,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:02:59.624909+00:00
MgaFRK1MEemaXnfPoQU_UQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,ade-nylylcyclase, C activation and by inhibiting ,. The facilitating effects of PG,TextQuoteSelector,TextPositionSelector,53575,53591,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:17:17.686859+00:00
MMYVkK1DEempE2PlEHMXPg,jgraPEon,https://europepmc.org/articles/PMC3231843/,peripheral arterial disease," of AMI, stroke, or symptomatic "," (PAD), clopidogrel administered",TextQuoteSelector,TextPositionSelector,18113,18140,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:12:49.936543+00:00
LbF58K1BEemfm18e4641Tw,jgraPEon,https://europepmc.org/articles/PMC3231843/,CD40L,tivated platelets. Shedding of s, from the surface of activated p,TextQuoteSelector,TextPositionSelector,27876,27881,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:58:26.042036+00:00
KTlOEq1PEem2_v-1DqmLow,jgraPEon,https://europepmc.org/articles/PMC3231843/,vitamin K-dependent Gla,"Tyro3, Axl, MerTK); through its ", module it interacts with phosph,TextQuoteSelector,TextPositionSelector,27187,27210,WS_GP,yes,[WS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:38:31.189635+00:00
KTd94q1MEemaXWcpGTRYxQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,adenylcyclase,naling cascades associated with , (Ac) down-regulation and decrea,TextQuoteSelector,TextPositionSelector,15559,15572,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:17:02.585582+00:00
JpoCPK1KEemit3_etFjVrA,jgraPEon,https://europepmc.org/articles/PMC3231843/, vasodilator-stimulated phosphoprotein, 4.2% of patients (36).Whereas a, (VASP)-tailored clopidogrel loa,TextQuoteSelector,TextPositionSelector,23254,23292,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:02:39.317754+00:00
JX8eKq1NEem6UacbrFGEaQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,GP,activation of the glycoprotein (,") IIb/IIIa receptor, resulting i",TextQuoteSelector,TextPositionSelector,14843,14845,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:24:05.941280+00:00
J00-4K1CEemnVm_qqYuTlA,jgraPEon,https://europepmc.org/articles/PMC3231843/,atherosclerosis ,tic (ischemic) complications of ,"(acute coronary syndrome (ACS), ",TextQuoteSelector,TextPositionSelector,9568,9584,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:05:24.742719+00:00
IvUopK1BEemtFc9CJlfPEw,jgraPEon,https://europepmc.org/articles/PMC3231843/,CD40L,ed upon aggregationCD40 ligand (,; CD 154)On activated platelets ,TextQuoteSelector,TextPositionSelector,27600,27605,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:58:07.972872+00:00
IcyVtK1DEemo-ec6nBZaBQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,CYP, activation by cytochrome P450 (,) liver isoenzymes. While the CA,TextQuoteSelector,TextPositionSelector,17930,17933,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:12:25.015793+00:00
I-0YUq1LEemTO0sjOZ75HQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,protein S,as a 44% sequence homology with ,", it does not show any anticoagu",TextQuoteSelector,TextPositionSelector,51306,51315,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:09:44.454118+00:00
HRmAhK1KEemoxb9veB0i_Q,jgraPEon,https://europepmc.org/articles/PMC3231843/,ABCB1,ulating clopidogrel absorption (,) have been associated with a hi,TextQuoteSelector,TextPositionSelector,21405,21410,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:02:23.629348+00:00
GyKLtq1CEemsLmNIizeNtA,jgraPEon,https://europepmc.org/articles/PMC3231843/,vis,"t all, these limitations. Vis-à-"," their net clinical benefit, the",TextQuoteSelector,TextPositionSelector,8855,8858,WT_GP,yes,[WT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:05:04.376439+00:00
GoY4Aq1LEem6TGtM2Owqcg,jgraPEon,https://europepmc.org/articles/PMC3231843/, limb ischemia,r previous revascularization for,. Participants are randomized to,TextQuoteSelector,TextPositionSelector,50547,50561,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:09:28.726484+00:00
GBRFkK1MEemmeg_T9rfMww,jgraPEon,https://europepmc.org/articles/PMC3231843/,ACS,rosis (acute coronary syndrome (,"), acute myocardial infarction (",TextQuoteSelector,TextPositionSelector,9610,9613,MIS_DS,yes,[MIS_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:16:34.143321+00:00
FlyxEq1PEemkPGdYZdGUqA,jgraPEon,https://europepmc.org/articles/PMC3231843/,thrombospondin,nt; retention of fibrinogen and , on the platelet surfaceImplicat,TextQuoteSelector,TextPositionSelector,11171,11185,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:37:59.717621+00:00
FkhO2K1BEemmVBcLTQXAcA,jgraPEon,https://europepmc.org/articles/PMC3231843/,MMP-2 ,"y potentiating PI3K activation, ",amplifies platelet aggregation r,TextQuoteSelector,TextPositionSelector,27340,27346,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:57:46.479215+00:00
Eya82K1NEemZ-aNeZiW6MQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,glycoprotein,"atelets (2,3). Upon activation, ", (Gp) IIb/IIIa (αIIbβ3 integrin),TextQuoteSelector,TextPositionSelector,10081,10093,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:23:35.059666+00:00
EMO6sK1LEemaCD9-xiLWAQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,intermittent claudication,ible for inclusion if they have , in conjunction with an ankle-br,TextQuoteSelector,TextPositionSelector,50437,50462,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:09:12.278675+00:00
D13gIK1KEemsQ5PvkZDwOw,jgraPEon,https://europepmc.org/articles/PMC3231843/,hypercoagulable states,"iabetes mellitus, inflammation, ",", low fibrinolytic potential), h",TextQuoteSelector,TextPositionSelector,20013,20035,WT_DS,no,[WT_DS],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:02:00.584864+00:00
CvLSsq1OEemVcOfdQVvd6A,jgraPEon,https://europepmc.org/articles/PMC3231843/,MMPs,(75).Matrix metalloproteinases (,) are involved in tissue remodel,TextQuoteSelector,TextPositionSelector,52160,52164,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:30:30.924474+00:00
Ck5RMK1MEemma5eSChMIbg,jgraPEon,https://europepmc.org/articles/PMC3231843/,Ac, associated with adenylcyclase (,) down-regulation and decreased ,TextQuoteSelector,TextPositionSelector,15574,15576,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:16:11.015669+00:00
C5ZqYK1BEempEfN2IX9JPw,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gαq,"o the P2 purinergic family, the ",-coupled receptor P2Y1 and the G,TextQuoteSelector,TextPositionSelector,11438,11441,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:57:28.685027+00:00
BsEbQq1CEem6PEt3hLaBHQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,cerebral infarction ,"64), 1,510 patients with recent ",were randomly assigned to receiv,TextQuoteSelector,TextPositionSelector,44558,44578,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:04:30.228548+00:00
Boaw8K1NEemozP9ga-iabg,jgraPEon,https://europepmc.org/articles/PMC3231843/,Gas6 receptors,ing the extracellular domain of ,", or by inactivation of RNA for ",TextQuoteSelector,TextPositionSelector,51905,51919,WS_GP,yes,[WS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:23:13.997580+00:00
BRHyNK1DEemXu-M8Dgz61w,jgraPEon,https://europepmc.org/articles/PMC3231843/,protein kinase C,ium concentration ([Ca+2]i) and ," (PKC) activation, leading to GP",TextQuoteSelector,TextPositionSelector,15352,15368,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:11:36.893813+00:00
BQygfq1LEemVbF_UDclruQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,peripheral artery disease,ime of inclusion. Patients with , (PAD) are eligible for inclusio,TextQuoteSelector,TextPositionSelector,50365,50390,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:08:52.587241+00:00
AnkBoK1PEemX1afRHLgmSg,jgraPEon,https://europepmc.org/articles/PMC3231843/,TAM, tyrosine kinases (RTKs) of the ," family (Tyro3, Axl, MerTK); thr",TextQuoteSelector,TextPositionSelector,27143,27146,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:37:26.342148+00:00
AZPXiK1KEembZJvak62PZg,jgraPEon,https://europepmc.org/articles/PMC3231843/,thrombotic thrombocytopenic purpura,"utropenia, aplastic anemia, and ", are the main limitations for a ,TextQuoteSelector,TextPositionSelector,17687,17722,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:01:37.239106+00:00
AGzbFrRIEemF509pJgB8hw,jgraPEon,https://europepmc.org/articles/PMC3231843/, tissue plasminogen activator,"(280 μg/kg/min) alone, full-dose"," (t-PA) alone, or cangrelor (35,",TextQuoteSelector,TextPositionSelector,35584,35613,WS_GP,no,WS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:34:54.615090+00:00
9KWqnK1JEemSLFvbNR6kEQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,aplastic anemia,"on (16). Diarrhea, neutropenia, ",", and thrombotic thrombocytopeni",TextQuoteSelector,TextPositionSelector,17666,17681,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:01:15.314278+00:00
9FmZDq1OEemfuDvPt6Qh3A,jgraPEon,https://europepmc.org/articles/PMC3231843/,sCD40L,on of the inflammatory markers (, and interleukin 6 and the expre,TextQuoteSelector,TextPositionSelector,26508,26514,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:37:02.718831+00:00
8qpvBK1CEemiqaP02kAikw,jgraPEon,https://europepmc.org/articles/PMC3231843/,P2Y1,"transmembrane domain receptors, "," and P2Y12, to activate platelet",TextQuoteSelector,TextPositionSelector,15141,15145,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:11:06.014799+00:00
8oygtq1AEemwTp-FUWN0Og,jgraPEon,https://europepmc.org/articles/PMC3231843/,PAR-1,g and vasodilating agentThrombin,; PAR-4 (secondary); GpIbαShape ,TextQuoteSelector,TextPositionSelector,10879,10884,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:56:46.802567+00:00
7M2rsK1BEemQABc-XO3Shw,jgraPEon,https://europepmc.org/articles/PMC3231843/, P2Y12,"brane domain receptors, P2Y1 and",", to activate platelets. P2Y1 is",TextQuoteSelector,TextPositionSelector,15149,15155,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:03:46.660655+00:00
6nCgQK1OEemX1Jt0t6RPxg,jgraPEon,https://europepmc.org/articles/PMC3231843/,RTKs,with receptor tyrosine kinases (,") of the Tyro3, Axl, and MerTK (",TextQuoteSelector,TextPositionSelector,51452,51456,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:36:45.984902+00:00
6V3wnK1MEem4cuuXejU-jQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,G12,ets. P2Y1 is coupled to Gαq and ,. Gαq is linked to a signaling p,TextQuoteSelector,TextPositionSelector,15207,15210,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:22:25.069913+00:00
6HyhEq1JEemoxHPWPAF__Q,jgraPEon,https://europepmc.org/articles/PMC3231843/, neutropenia,"ent implantation (16). Diarrhea,",", aplastic anemia, and thromboti",TextQuoteSelector,TextPositionSelector,17652,17664,CRT_DS,no,CRT_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:00:55.240523+00:00
62137tCOEemScWMNkHj1VQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,G28-5,nted by an anti-CD40L antibody (,)Open in a separate windowPrasug,TextQuoteSelector,TextPositionSelector,27980,27985,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:13:06.255888+00:00
5vfbAq1LEemwvf9CI0jvog,jgraPEon,https://europepmc.org/articles/PMC3231843/,5HT-2A receptors, Gai-coupled receptors)Serotonin,Shape change; platelet recruitme,TextQuoteSelector,TextPositionSelector,11091,11107,WS_GP,yes,[WS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:15:11.429961+00:00
5_onwq1AEemipEfVS94aSA,jgraPEon,https://europepmc.org/articles/PMC3231843/,thrombin,"2 (T×A2), serotonin (5-HT), and ",) recruit and activate additiona,TextQuoteSelector,TextPositionSelector,10005,10013,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:56:29.107063+00:00
4dKDiK1CEemUgjezUGkBGg,jgraPEon,https://europepmc.org/articles/PMC3231843/,P2Y1,-coupled P2Y1; Gai-coupled P2Y12,: shape change; P2Y12: aggregati,TextQuoteSelector,TextPositionSelector,10579,10583,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:10:37.636943+00:00
4cj26q1OEem42ks7H5y_3Q,jgraPEon,https://europepmc.org/articles/PMC3231843/,renal dysfunction,"(e.g. elderly, low body-weight, ",) and avoided in patients with h,TextQuoteSelector,TextPositionSelector,42316,42333,MIS_DS,no,MIS_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:36:31.300080+00:00
4ZKqKK1NEemYj5tY0X-jzQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,Matrix metalloproteinases,tidylserine-containing membranes, (MMPs)By potentiating PI3K acti,TextQuoteSelector,TextPositionSelector,27275,27300,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:29:21.314837+00:00
4L3tQK1KEempIyfnJmh03Q,jgraPEon,https://europepmc.org/articles/PMC3231843/,stroke,ers of serious vascular events (,", acute coronary syndrome, or va",TextQuoteSelector,TextPositionSelector,44816,44822,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:07:51.766257+00:00
3wJ7RLRGEemXLa9s4oeifw,jgraPEon,https://europepmc.org/articles/PMC3231843/,acute coronary syndrome,"erious vascular events (stroke, ",", or vascular death) were second",TextQuoteSelector,TextPositionSelector,44824,44847,WS_DS,no,WS_DS,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:26:49.134737+00:00
3h7C2K1MEemYicO4tAgjXg,jgraPEon,https://europepmc.org/articles/PMC3231843/,fibrin,"idges, which, once converted to ",", ultimately contribute to throm",TextQuoteSelector,TextPositionSelector,10227,10233,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:22:06.305376+00:00
2wHoYq1JEemcmmv-sgW5Vw,jgraPEon,https://europepmc.org/articles/PMC3231843/, purinergic receptor,raction of ADP with its platelet, and to determine the inhibition,TextQuoteSelector,TextPositionSelector,17200,17220,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:00:32.734917+00:00
2XToAK1OEemaZHtak5qmMw,jgraPEon,https://europepmc.org/articles/PMC3231843/,receptor tyrosine kinases , it interacts with the membrane ,"(RTKs) of the TAM family (Tyro3,",TextQuoteSelector,TextPositionSelector,27103,27129,MIS-GP,yes,[MIS-GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:36:17.339181+00:00
25AHwq1AEemTGiNP3nh6KQ,jgraPEon,https://europepmc.org/articles/PMC3231843/,stroke,"al infarction (−32%), non-fatal "," (−25%), and of cardiovascular d",TextQuoteSelector,TextPositionSelector,8694,8700,CRT_DS,yes,[CRT_DS][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T11:56:08.165157+00:00
1eLrurRHEem8hAdX9gBRqA,jgraPEon,https://europepmc.org/articles/PMC3231843/,P2Y12 receptors,ined inhibition of thrombin and , leads to a synergistic inhibito,TextQuoteSelector,TextPositionSelector,13978,13993,MIS_GP,no,MIS_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-08-01T10:33:43.207706+00:00
0NWFuK1LEemn2S9ajim2QA,jgraPEon,https://europepmc.org/articles/PMC3231843/, (Gp) IIb,"). Upon activation, glycoprotein",/IIIa (αIIbβ3 integrin) mediates,TextQuoteSelector,TextPositionSelector,10093,10102,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:14:34.586612+00:00
0DaNDK1JEemQAY8Cuct4JA,jgraPEon,https://europepmc.org/articles/PMC3231843/,PKC,([Ca+2]i) and protein kinase C (,") activation, leading to GP IIb/",TextQuoteSelector,TextPositionSelector,15370,15373,CRT_GP,no,CRT_GP,,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:00:14.221867+00:00
-uljoq1KEemkNGfvvVERpg,jgraPEon,https://europepmc.org/articles/PMC3231843/,CER,treatment of CAD patients. TRA* ," (71) is a prospective, randomiz",TextQuoteSelector,TextPositionSelector,49502,49505,WT_GP,no,[WT_GP],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:08:35.395346+00:00
-YCKQq1NEem4diuKpoJGlA,jgraPEon,https://europepmc.org/articles/PMC3231843/,MerTK ,"s (RTKs) of the Tyro3, Axl, and ","(TAM) family, Gas6 employs a uni",TextQuoteSelector,TextPositionSelector,51481,51487,MIS_GP,yes,[MIS_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T13:30:01.617178+00:00
-5Bo9K1BEemUgSNS67C4JA,jgraPEon,https://europepmc.org/articles/PMC3231843/,CD40 ligand,ol and released upon aggregation, (CD40L; CD 154)On activated pla,TextQuoteSelector,TextPositionSelector,27587,27598,CRT_GP,yes,[CRT_GP][ALL],,acct:farheen.s@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T12:04:11.371670+00:00
